This is a working overview of human growth hormone, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-30. Anything still debated is marked as such rather than presented as settled.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
In the United States, heroin is not accepted as medically useful. Its classification as a Schedule I drug means it has "no currently accepted medical use and a high potential for abuse." Under the generic name diamorphine, heroin is prescribed as a strong pain medication in the United Kingdom, where it is administered via oral, subcutaneous, intramuscular, intrathecal, intranasal or intravenous routes. It may be prescribed for the treatment of acute pain, such as in severe physical trauma, myocardial infarction, post-surgical pain and chronic pain, including end-stage terminal illnesses. In other countries it is more common to use morphine or other strong opioids in these situations. The UK's National Institute for Health and Clinical Excellence has produced guidance on the management of caesarean section, which recommends the use of intrathecal or epidural diamorphine for post-operative pain relief. For women who have had intrathecal opioids including diamorphine, there should be a minimum hourly observation of respiratory rate, sedation and pain scores for at least 12 hours if risk factors for respiratory depression are present. Women should be offered diamorphine (up to 0.3mg intrathecally) for intra- and postoperative analgesia because it reduces the need for supplemental analgesia after a caesarean section. Epidural diamorphine (up to 3mg) is a suitable alternative. Diamorphine continues to be widely used in palliative care in the UK, where it is commonly given by the subcutaneous route, often via a syringe driver if patients cannot easily swallow morphine solution.
== Biography == Born on 27 September 1958 in the Indian state of Maharashtra, K. V. Subba Rao graduated in science from the University of Pune and before starting his career by joining Malti-Chem Research Centre, Baroda, he secured his master's degree also from the same university in 1979. Subsequently, he did his doctoral studies under Sukhdev at Maharaja Sayajirao University of Baroda and moved to Johns Hopkins University in 1983 for his post-doctoral studies at their Division of Environmental Chemistry where he worked with Miles R. Chedekel. After working for two years there, he joined the laboratory of Fred C. Fox at the University of California and worked there for three more years. Returning to India in 1988, he joined the International Centre for Genetic Engineering and Biotechnology where he held different positions as that of a research scientist (1988–91) and research assistant (1991–94) and was the Group Leader of the Immunology Group (1994-2015).
=== Special populations === Globally, bromazepam is contraindicated and should be used with caution in women who are pregnant, the elderly, patients with a history of alcohol or other substance abuse disorders and children. In 1987, a team of scientists led by Ochs reported that the elimination half-life, peak serum concentration, and serum free fraction are significantly elevated and the oral clearance and volume of distribution significantly lowered in elderly subjects. The clinical consequence is that the elderly should be treated with lower doses than younger patients. Bromazepam may affect driving and ability to operate machinery. Bromazepam is pregnancy category D, a classification that means that bromazepam has been shown to cause harm to the unborn child. The Hoffman LaRoche product information leaflet warns against breast feeding while taking bromazepam. There has been at least one report of sudden infant death syndrome linked to breast feeding while consuming bromazepam.
Sources: en.wikipedia.org
Kimon Georgiev established the political circle "Zveno" with Damyan Velchev in 1927, firstly as a non-partisan organization that aims to improve the socio-political climate in the country. It proclaimed its support for authoritarian power, raised above the strictly party interests, with national purpose. The fascists influence on the Zveno is undisputed, but its not characterized as fascist, but a corporate statism in which it mainly drew inspiration from Italian fascism. Georgiev ceased ties with the Democratic Alliance in 1930 and after the 1931 Bulgarian parliamentary election, he was no longer a deputy of his group. He became a leader of the Zveno and in the beginning of 1932, a newspaper Izgrev was published with one of the editors being Georgiev himself. He published articles in which he criticized communism and the Soviet Union, as well as declaring for a strong government "in the name of order and state intervention in economic life." The primary component of Zveno's ideology was anti-communism, which embraced strong "supra-party" authoritarian bourgeois power of the fascist variety while rejecting the bourgeois democratic system of governance. The bulk of Zveno members joined Aleksander Tsankov's Popular Social Movement in January 1934, but a smaller group led by Kimon Georgiev kept the group operating independently. Zveno was a little organization with little social interaction. It made touch with the Military League, which was once more planning a violent change of government.
=== Topoisomerase-mediated ligation === Topoisomerase can be used instead of ligase for ligation, and the cloning may be done more rapidly without the need for restriction digest of the vector or insert. In this TOPO cloning method a linearized vector is activated by attaching topoisomerase I to its ends, and this "TOPO-activated" vector may then accept a PCR product by ligating to both of the 5' ends of the PCR product, the topoisomerase is released and a circular vector is formed in the process.
Deltamethrin is a pyrethroid ester insecticide. Deltamethrin plays a key role in controlling malaria vectors, and is used in the manufacture of long-lasting insecticidal mosquito nets; however, resistance of mosquitos and bed bugs to deltamethrin has seen a widespread increase. Deltamethrin is toxic to aquatic life, particularly fish. Although generally considered safe to use around humans, it is still neurotoxic. It is an allergen and causes asthma in some people.
La Niña causes mostly the opposite effects of El Niño: above-average precipitation across the northern Midwest, the northern Rockies, Northern California, and the Pacific Northwest's southern and eastern regions. Meanwhile, precipitation in the southwestern and southeastern states, as well as southern California, is below average. This also allows for the development of many stronger-than-average hurricanes in the Atlantic and fewer in the Pacific. ENSO is linked to rainfall over Puerto Rico. During an El Niño, snowfall is greater than average across the southern Rockies and Sierra Nevada mountain range, and is well-below normal across the Upper Midwest and Great Lakes states. During a La Niña, snowfall is above normal across the Pacific Northwest and western Great Lakes. In Canada, La Niña will, in general, cause a cooler, snowier winter, such as the near-record-breaking amounts of snow recorded in the La Niña winter of 2007–2008 in eastern Canada. In the spring of 2022, La Niña caused above-average precipitation and below-average temperatures in the state of Oregon. April was one of the wettest months on record, and La Niña effects, while less severe, were expected to continue into the summer. Over North America, the main temperature and precipitation impacts of El Niño generally occur in the six months between October and March. In particular, the majority of Canada generally has milder than normal winters and springs, with the exception of eastern Canada where no significant impacts occur.
Sources: en.wikipedia.org
== Short-term feed restriction == Recent studies on short-term effects of a meal or the absence of a meal has revealed that lepa1 expression specifically peaks in the peripheral tissues after 6 – 9 hr in the unfed fish. This suggests that the transcript specific response could be associated with the absence of food. Conversely, since the unfed fish had not received food for 33 hr (24 + 9 hr), the peaks could represent an unrelated effect. Each lepa1 peak occurred during a phase of falling plasma Lep, and since this occurred in both fed and unfed fish, the temporal upregulation of lepa1 does not in fact appear to be specifically related to the absence of food. The earliest peak of lepa1 occurred in the white muscle, which represents an important lipid reservoir in Atlantic salmon. Unlike pufferfish, which utilizes the liver as a major lipid repository, Atlantic salmon shows that despite a high visceral lipid content, hepatocytes contain few lipid droplets compared to other fish species, yet are an important site for leptin expression. Moen and colleagues reported that both lepa1 and lepa2 peaked at 9 hr in the liver of unfed fish. By contrast, however, studies in common carp demonstrated a peak in leptin-I(lepa1) and leptin–II (lepa2) in liver at 3 and 6 hr post feeding respectively. The earlier expression response of leptins in common carp likely reflects the higher temperature under which the experiments were conducted, but contrasts the findings of upregulation of lepa1 due to the absence of food.
Neither of these ocular signs should be confused with exophthalmos (protrusion of the eyeball), which occurs specifically and uniquely in hyperthyroidism caused by Graves' disease (note that not all exophthalmos is caused by Graves' disease, but when present with hyperthyroidism is diagnostic of Graves' disease). This forward protrusion of the eyes is due to immune-mediated inflammation in the retro-orbital (eye socket) fat. Exophthalmos, when present, may exacerbate hyperthyroid lid-lag and stare.
== Development and regulation in the United States == The solid filiform needle used in dry needling is regulated by the FDA as a Class II medical device described in the code titled "Sec. 880.5580 Acupuncture needle is a device intended to pierce the skin in the practice of acupuncture". Per the Food and Drug Act of 1906 and the subsequent amendments to said act, the FDA definition applies to how the needles can be marketed and does not mean that acupuncture is the only medical procedure where these needles can be used. Dry needling using such a needle contrasts with the use of a hollow hypodermic needle to inject substances such as saline solution, botox or corticosteroids to the same point. The founder of Integrative Systemic Dry Needling (ISDN), Yun-Tao Ma, has spearheaded the "dry needling" movement in the United States. Ma states, "Although ISDN originated in traditional Chinese methods, it has developed from the ancient empirical approach to become modern medical art rooted in evidence-based thinking and practice." Ma also states that, "Dry needling technique is a modern Western medical modality that is not related to traditional Chinese acupuncture in any way. Dry needling has its own theoretical concepts, terminology, needling technique, and clinical application."
She said that TheJosh would have to schedule their workouts in two-week chunks, as a week is seven days, supposedly from Monday to Sunday. The Britannica Dictionary writes that a week is usually defined as Sunday to Saturday in American English, and Monday to Sunday in British English. TheJosh's account stated they were from the U.S., while Justin27's location was not listed.
Eyadéma died suddenly on 5 February 2005. According to the Togolese Constitution, after the president's death, the president of the National Assembly should become acting president. At the time of Eyadéma's death, the National Assembly president Fambaré Ouattara Natchaba was out of the country, and Gnassingbé was thus sworn in as president by the Togolese Army to "ensure stability". Many believe that Natchaba did not want to come back to Togo due to fears of assassination by the Gnassingbé clan. The army wanted him to resign his position and allow Gnassingbé to legally take over. The African Union denounced Gnassingbé's assumption of power as a military coup.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.